These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

917 related articles for article (PubMed ID: 17622750)

  • 1. Rosiglitazone increases PPARgamma in renal tubular epithelial cells and protects against damage by hydrogen peroxide.
    Sommer M; Wolf G
    Am J Nephrol; 2007; 27(4):425-34. PubMed ID: 17622750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
    Lin MS; Chen WC; Bai X; Wang YD
    J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.
    Yang FG; Zhang ZW; Xin DQ; Shi CJ; Wu JP; Guo YL; Guan YF
    Acta Pharmacol Sin; 2005 Jun; 26(6):753-61. PubMed ID: 15916743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells.
    Bruemmer D; Yin F; Liu J; Berger JP; Sakai T; Blaschke F; Fleck E; Van Herle AJ; Forman BM; Law RE
    Circ Res; 2003 Aug; 93(4):e38-47. PubMed ID: 12881480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apoptosis and proliferation of cultured mesangial cells isolated from kidneys of rosiglitazone-treated pregnant diabetic rats.
    Weissgarten J; Berman S; Efrati S; Rapoport M; Averbukh Z; Feldman L
    Nephrol Dial Transplant; 2006 May; 21(5):1198-204. PubMed ID: 16449288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rosiglitazone induces caveolin-1 by PPARgamma-dependent and PPRE-independent mechanisms: the role of EGF receptor signaling and its effect on cancer cell drug resistance.
    Tencer L; Burgermeister E; Ebert MP; Liscovitch M
    Anticancer Res; 2008; 28(2A):895-906. PubMed ID: 18507034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The PPARgamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice.
    Hwang J; Kleinhenz DJ; Rupnow HL; Campbell AG; Thulé PM; Sutliff RL; Hart CM
    Vascul Pharmacol; 2007 Jun; 46(6):456-62. PubMed ID: 17337254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rosiglitazone, a PPARgamma ligand, modulates signal transduction pathways during the development of acute TNBS-induced colitis in rats.
    Sánchez-Hidalgo M; Martín AR; Villegas I; de la Lastra CA
    Eur J Pharmacol; 2007 May; 562(3):247-58. PubMed ID: 17343846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The PPARgamma ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines.
    Morosetti R; Servidei T; Mirabella M; Rutella S; Mangiola A; Maira G; Mastrangelo R; Koeffler HP
    Int J Oncol; 2004 Aug; 25(2):493-502. PubMed ID: 15254749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective effect of peroxisome proliferator-activated receptor-gamma agonists on activated renal proximal tubular epithelial cells in IgA nephropathy.
    Xiao J; Leung JC; Chan LY; Guo H; Lai KN
    Nephrol Dial Transplant; 2009 Jul; 24(7):2067-77. PubMed ID: 19155534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rosiglitazone inhibits insulin-like growth factor‑1-induced polycystic kidney disease cell growth and p70S6 kinase activation.
    Liu C; Zhang Y; Yuan L; Fu L; Mei C
    Mol Med Rep; 2013 Sep; 8(3):861-4. PubMed ID: 23864113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PPAR gamma protects cardiomyocytes against oxidative stress and apoptosis via Bcl-2 upregulation.
    Ren Y; Sun C; Sun Y; Tan H; Wu Y; Cui B; Wu Z
    Vascul Pharmacol; 2009; 51(2-3):169-74. PubMed ID: 19540934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism.
    Moulin D; Bianchi A; Boyault S; Sebillaud S; Koufany M; Francois M; Netter P; Jouzeau JY; Terlain B
    Arthritis Rheum; 2005 Mar; 52(3):759-69. PubMed ID: 15751073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of PPARgamma is not involved in butyrate-induced epithelial cell differentiation.
    Ulrich S; Wächtershäuser A; Loitsch S; von Knethen A; Brüne B; Stein J
    Exp Cell Res; 2005 Oct; 310(1):196-204. PubMed ID: 16112107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of curcumin on peroxisome proliferator-activated receptor gamma expression and nuclear translocation/redistribution in culture-activated rat hepatic stellate cells.
    Cheng Y; Ping J; Xu LM
    Chin Med J (Engl); 2007 May; 120(9):794-801. PubMed ID: 17531121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of proliferation and transforming growth factor beta3 protein expression by peroxisome proliferators-activated receptor gamma ligands in human uterine leiomyoma cells.
    Zhang CH; Wen ZQ; Li JF; Li CZ; Shi M; Yang GW; Lan SM; Zhu Y; Wang F; Zhang YJ; Wang YY; Zhang H
    Chin Med J (Engl); 2008 Jan; 121(2):166-71. PubMed ID: 18272045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ischemic preconditioning reveals that GLT1/EAAT2 glutamate transporter is a novel PPARgamma target gene involved in neuroprotection.
    Romera C; Hurtado O; Mallolas J; Pereira MP; Morales JR; Romera A; Serena J; Vivancos J; Nombela F; Lorenzo P; Lizasoain I; Moro MA
    J Cereb Blood Flow Metab; 2007 Jul; 27(7):1327-38. PubMed ID: 17213861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The peroxisome proliferator-activated receptor gamma ligand troglitazone induces apoptosis and p53 in rat granulosa cells.
    Lovekamp-Swan T; Chaffin CL
    Mol Cell Endocrinol; 2005 Apr; 233(1-2):15-24. PubMed ID: 15767042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer.
    Mansour M; Schwartz D; Judd R; Akingbemi B; Braden T; Morrison E; Dennis J; Bartol F; Hazi A; Napier I; Abdel-Mageed AB
    Int J Oncol; 2011 Feb; 38(2):537-46. PubMed ID: 21170507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo.
    Yu J; Qiao L; Zimmermann L; Ebert MP; Zhang H; Lin W; Röcken C; Malfertheiner P; Farrell GC
    Hepatology; 2006 Jan; 43(1):134-43. PubMed ID: 16374840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.